Aarey Drugs & Pharmaceuticals Ltd

Aarey Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 March 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Aarey Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Aarey Drugs & Pharmaceuticals Ltd witnessed a robust surge in its share price on 26 Feb 2026, hitting the upper circuit limit with an intraday gain of 8.31%, reflecting intense buying interest and a significant reversal after two days of decline. The stock outperformed its sector and broader market indices, signalling renewed investor confidence despite its recent strong sell rating.

Shares of Aarey Drugs & Pharmaceuticals Ltd tumbled sharply on 24 Feb 2026, hitting the maximum permissible daily loss limit of 9.99% and closing at ₹72.45. The micro-cap pharmaceutical company faced intense selling pressure, with volumes surging and the stock underperforming its sector and broader market indices amid a wave of panic selling and unfilled supply.

Aarey Drugs & Pharmaceuticals Ltd witnessed a significant surge in its share price on 23 Feb 2026, hitting the upper circuit limit of 10% and closing at ₹83.05. This remarkable rally was driven by strong buying interest, sustained investor participation, and a notable gap-up opening, marking a continuation of the stock’s impressive five-day winning streak.

Aarey Drugs & Pharmaceuticals Ltd witnessed a remarkable surge on 20 Feb 2026, hitting its upper circuit limit with a robust 7.86% gain, driven by intense buying interest and heightened volatility. The stock’s performance outpaced its sector and the broader market, reflecting renewed investor enthusiasm despite its current strong sell rating.

Aarey Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 November 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 16 February 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Aarey Drugs & Pharmaceuticals Ltd. reported a challenging third quarter for FY2026, with net profit declining 44.12% quarter-on-quarter to ₹0.57 crores from ₹1.02 crores in Q2 FY26. The year-on-year comparison proved even more concerning, with profits plunging 20.83% from ₹0.72 crores in Q3 FY25. The Mumbai-based pharmaceutical company, with a market capitalisation of ₹191.93 crores, continues to grapple with operational headwinds that have eroded both topline growth and bottom-line profitability.

Aarey Drugs & Pharmaceuticals Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock's medium to long-term outlook within the Pharmaceuticals & Biotechnology sector.

Aarey Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 Nov 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 05 February 2026, providing investors with the latest comprehensive view of the company’s position.

Shares of Aarey Drugs & Pharmaceuticals Ltd plunged to their lower circuit limit on 2 Feb 2026, closing at ₹61.08, marking a maximum daily loss of 4.99%. The stock witnessed intense selling pressure, with volumes concentrated near the day’s low, signalling panic selling and a sharp decline in investor confidence amid deteriorating fundamentals and weak market sentiment.

Shares of Aarey Drugs & Pharmaceuticals Ltd plunged to their lower circuit limit on 1 Feb 2026, succumbing to intense selling pressure that saw the stock lose nearly 5% in a single session. The micro-cap pharmaceutical company’s stock performance has deteriorated sharply, reflecting mounting investor concerns and a sustained downtrend that has wiped out over 8% in the past two days.

Aarey Drugs & Pharmaceuticals Ltd witnessed a robust surge in its share price on 28 Jan 2026, hitting the upper circuit limit of 4.99% to close at ₹71.30. This significant price movement was driven by intense buying interest, resulting in a trading halt due to regulatory freeze mechanisms. The stock outperformed its sector and broader market indices, reflecting renewed investor enthusiasm despite its current Strong Sell rating.

Aarey Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 25 January 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.